Compliance Information
ESMO 2023 is organised by the European Society of Medical Oncology (based in Lugano, Switzerland). The Congress is provided to international HCPs with a majority from Europe and is following the EFPIA guidance/code.
EFPIA accreditation
The EFPIA accreditation submission has been taken care by ESMO, as ESMO is the content owner and organizer of the ESMO Congresses. Please do not submit any accreditation request to EFPIA on behalf of ESMO. ESMO 2023 submission has been assigned with the reference number EMT27870 and the current status of the event is provisionally compliant. You can see and follow the submission status here.
Should you have any queries or doubts on the EFPIA accreditation for ESMO Congresses do not hesitate to contact satellites@esmo.org.
On-site regulation
Participants fully registered to the congress, visitors wearing the visitors’ badge, exhibitors wearing the exhibitor badge and agencies wearing the Industry Satellite badge have the right to attend satellite symposia sessions. For ESMO 2023, different badge-coloured stripes will be used to identify delegates as prescribers or non-prescribers. This decision has been taken to comply with prescription-only medicines promotional legislation, both European and national. (i) Delegates attending the Congress will be responsible when deciding which parts or areas of the congress they access to or visit, and (ii) By previously identifying their profile, pharmaceutical companies will be responsible when deciding how they engage or interact with participants, according to European legislation and any applicable code of practice.
Online regulation
Satellite symposia sessions will be accessible for all registered delegates; however, companies may add a disclaimer on top of their Satellite Symposium Virtual Space.